课题基金 / 基金详情

Development of Faster, Lower-Cost, High-Sensitivity Immunoassay for Specific Determination of Glucagon Using EAP-derived Monoclonal Antibodies

Development of Faster, Lower-Cost, High-Sensitivity Immunoassay for Specific Determination of Glucagon Using EAP-derived Monoclonal Antibodies
使用 EAP 衍生的单克隆抗体开发更快、成本更低、高灵敏度的免疫测定法,用于特异性测定胰高血糖素
批准号:
9107441
负责人:
MARK GEISBERG
金额:
$22.01万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-08-01 至 2018-01-31

项目摘要

项目成果

MARK GEISBERG的其他基金

相似基金

相关文献

中文摘要
翻译
 说明(申请人提供):高血糖素是一种在调节葡萄糖代谢中起核心作用的多肽荷尔蒙,许多疾病,包括1型和2型糖尿病,都是以高血糖素水平异常为特征的。这一领域的临床实践和研究都受到缺乏适当特异和灵敏的血液中胰高血糖素水平分析的阻碍。该项目的目标是开发和验证改进的免疫测定法,使用最近制造的针对胰高血糖素的超特异性单抗来测定胰高血糖素。这些检测提供的新能力可以显著提高对葡萄糖稳态紊乱的理解,同时使这种关键荷尔蒙的准确临床测试成为可能。
英文摘要
 DESCRIPTION (provided by applicant): Glucagon is a peptide hormone with a central role in the regulation of glucose metabolism, and many disorders, including Type 1 and Type 2 diabetes, are notable for abnormalities in glucagon levels. Both clinical practice and research in this field are hampered by the lack of appropriately specific and sensitive assays for glucagon levels in blood. The goal of this project is to develop and validate improved immunoassays for glucagon determination, using recently made hyperspecific monoclonal antibodies to glucagon. The new capabilities offered by these assays can lead to significant advances in the understanding of glucose homeostasis disorders and, in parallel, enable accurate clinical testing for this crucial hormone.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
EAP-Derived Monoclonal Antibodies for Phenotyping Immune Cells of Animal Model of Disease
  • 批准号:
    10933282
  • 项目类别:
  • 资助金额:
    $75.0万
  • 财政年份:
    2023
  • 负责人:
    MARK GEISBERG
  • 依托单位:
A Rapid and Inexpensive Point-of-Care Test for Beta-Thalassemia Carriers
  • 批准号:
    10053692
  • 项目类别:
  • 资助金额:
    $34.85万
  • 财政年份:
    2020
  • 负责人:
    MARK GEISBERG
  • 依托单位:
EAP-DERIVED MONOCLONAL ANTIBODIES FOR PHENOTYPING GUINEA PIG IMMUNE CELLS.
  • 批准号:
    10291475
  • 项目类别:
  • 资助金额:
    $60.0万
  • 财政年份:
    2020
  • 负责人:
    MARK GEISBERG
  • 依托单位:
Rapid LFIA blood test for SCD using highly specific monoclonal antibodies
  • 批准号:
    9170967
  • 项目类别:
  • 资助金额:
    $50.0万
  • 财政年份:
    2014
  • 负责人:
    MARK GEISBERG
  • 依托单位:
海外基金